Autistic disorder Trials in Chapel Hill, United States
Conditions / Autistic disorder / Chapel Hill, United States
Autistic disorder is a medical condition with active clinical research programs worldwide.
12 total trials for this combination
Showing top 10 of 12 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00365859 | Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD) | COMPLETED | PHASE3 |
| NCT00619190 | Study of Aripiprazole to Treat Children and Adolescents With Autism | COMPLETED | PHASE2 |
| NCT00787111 | Extended Management and Measurement of Autism | TERMINATED | PHASE3 |
| NCT01592786 | An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) | COMPLETED | PHASE2 |
| NCT01592747 | Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine | COMPLETED | PHASE2 |
| NCT01431326 | Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care | COMPLETED | — |
| NCT00332241 | Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD) | COMPLETED | PHASE3 |
| NCT01731119 | Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents | COMPLETED | PHASE2 |
| NCT01592773 | Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) | TERMINATED | PHASE2 |
| NCT00515320 | Study of Fluoxetine in Autism | COMPLETED | PHASE3 |